Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech US. The ACTIA Platform complements Cellular Origins’ existing approach and will accelerate and expand R&D efforts to further develop the Company’s robotic solution for automated cell therapy manufacturing, Constellation™.
IRA will reduce out-of-pocket spending among some Part D enrollees by $7.4B in 2025, HHS report says
The Inflation Reduction Act could lower out-of-pocket costs by around $7.4 billion in 2025 for more than a third of all Americans enrolled in Medicare
July 8, 2023